MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.90
-2.99
-4.91%
After Hours: 56.60 -1.3 -2.25% 19:56 03/27 EDT
OPEN
59.88
PREV CLOSE
60.89
HIGH
60.03
LOW
56.72
VOLUME
1.85M
TURNOVER
--
52 WEEK HIGH
123.99
52 WEEK LOW
35.25
MARKET CAP
8.57B
P/E (TTM)
-81.4575
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EXAS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EXAS stock price target is 112.43 with a high estimate of 135.00 and a low estimate of 75.00.

EPS

EXAS News

More
  • Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
  • Zacks · 2d ago
  • Epic, Exact Sciences among Wisconsin tech firms responding to COVID-19
  • American City Business Journals · 2d ago
  • Exact Sciences Grows on New Deals, Down on Coronavirus Scare
  • Zacks · 5d ago
  • Is Exact Sciences Corporation's (NASDAQ:EXAS) CEO Pay Fair?
  • Simply Wall St. · 03/21 14:22

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About EXAS

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
More

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.